

**ANNOUNCEMENT**

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as "MGRC" or "the Company") and its subsidiaries ("the Group") hereby announce the following unaudited results for the fourth quarter ended 30 June 2013.

**A PRESENTATION OF RESULTS**
**I CONDENSED STATEMENT OF COMPREHENSIVE INCOME**

for the financial period ended	4th Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	30.6.2013	30.6.2012	30.6.2013	30.6.2012
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Revenue	257	1,068	536	9,843
Interest income from fixed deposits	40	86	199	485
Marketing and distribution	(30)	(111)	(427)	(614)
Employee benefits and expense	(38)	(821)	(3,418)	(4,147)
Depreciation and amortisation	(1,817)	(510)	(3,359)	(1,911)
Lab consumables	(148)	(194)	(413)	(2,162)
Research collaboration costs	(105)	(40)	(105)	(1,040)
Exclusive license fee <sup>^</sup>	63	(63)	(123)	(249)
System maintenance cost <sup>^</sup>	301	(301)	(602)	(1,204)
Administrative expenses	(296)	(695)	(2,022)	(2,540)
Bad debts written off	(52)	-	(52)	-
Foreign exchange gain / (loss)	-	-	-	(5)
<b>Profit / (loss) from operations</b>	<b>(1,825)</b>	<b>(1,581)</b>	<b>(9,786)</b>	<b>(3,544)</b>
Finance costs	-	-	-	-
Share of profit / (loss) in jointly controlled entity	1,069	-	1,033	-
<b>Profit / (loss) before tax</b>	<b>(756)</b>	<b>(1,581)</b>	<b>(8,753)</b>	<b>(3,544)</b>
Income tax expenses	(10)	(22)	(48)	(116)
<b>Profit / (loss), net of tax, representing total comprehensive income</b>	<b>(766)</b>	<b>(1,603)</b>	<b>(8,801)</b>	<b>(3,660)</b>
<b>Profit / (loss) attributable to:</b>				
Owners of the parent	(766)	(1,603)	(8,801)	(3,660)
Non-controlling interests	-	-	-	-
<b>Net profit / (loss) for the period</b>	<b>(766)</b>	<b>(1,603)</b>	<b>(8,801)</b>	<b>(3,660)</b>
<b>Earnings / (Loss) per share (EPS) attributable to the equity holders of the Company (sen)</b>				
Basic EPS	(0.81)	(1.70)	(9.35)	(3.89)
Diluted EPS	N/A	N/A	N/A	N/A

The unaudited condensed statement of comprehensive income should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

Note:-

There is no income/expense in relation to other income including investment income, provision for/write-off of inventories, gain/loss on disposal of quoted or unquoted investments or properties, impairment of assets, gain/loss on derivatives, or exceptional items.

<sup>^</sup> Kindly refer to note B (xiv), for further information.

**A PRESENTATION OF RESULTS (cont.)**
**II CONDENSED STATEMENT OF FINANCIAL POSITION**

as at	30.6.2013 (RM'000)	30.6.2012 (RM'000)
<b>ASSETS</b>		
<b>NON-CURRENT ASSETS</b>		
Plant and equipment	3,041	5,653
Intangible asset	3,615	4,226
Investment in jointly controlled entity	7,826	-
<b>CURRENT ASSETS</b>		
Trade and other receivables	457	6,887
Inventories	903	785
Other current assets	81	957
Tax recoverable	30	-
Cash and bank balances	5,378	12,110
<b>TOTAL ASSETS</b>	<b>21,331</b>	<b>30,618</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY ATTRIBUTABLE TO OWNERS OF THE PARENT</b>		
Share capital	9,410	9,410
Share premium	14,755	14,755
(Accumulated losses)/Retained earnings	(3,950)	4,851
<b>TOTAL EQUITY</b>	<b>20,215</b>	<b>29,016</b>
<b>CURRENT LIABILITIES</b>		
Trade and other payables	1,116	1,574
Tax payable	-	28
<b>TOTAL LIABILITIES</b>	<b>1,116</b>	<b>1,602</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>21,331</b>	<b>30,618</b>
Net assets (RM'000)	20,215	29,016
Net assets per share attributable to equity holders of the Company (sen)	21.48	30.84

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

**A PRESENTATION OF RESULTS (cont.)**
**III CONDENSED STATEMENT OF CHANGES IN EQUITY**

	Equity, Total	← Non-Distributable →		Distributable Retained Earnings / (Accumulated Losses)
		Share Capital	Share Premium	
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
<b>for the financial year ended 30 June 2012</b>				
Opening balance at 1 July 2011	32,676	9,410	14,755	8,511
Total comprehensive income / (loss)	(3,660)	-	-	(3,660)
<b>Closing balance at 30 June 2012</b>	<b>29,016</b>	<b>9,410</b>	<b>14,755</b>	<b>4,851</b>
<b>for the financial year ended 30 June 2013</b>				
Opening balance at 1 July 2012	29,016	9,410	14,755	4,851
Total comprehensive income / (loss)	(8,801)	-	-	(8,801)
<b>Closing balance at 30 June 2013</b>	<b>20,215</b>	<b>9,410</b>	<b>14,755</b>	<b>(3,950)</b>

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

**A PRESENTATION OF RESULTS (cont.)**
**IV CONDENSED STATEMENT OF CASH FLOWS**

for the financial period ended	Year-to-Date	
	Current Year	Previous Year
	30.6.2013 (RM'000)	30.6.2012 (RM'000)
<b>Cash flows from operating activities</b>		
Profit / (loss) before tax	(8,753)	(3,544)
Adjustments for:		
Share of jointly controlled entity	(1,033)	-
Amortisation of intangible assets	611	611
Depreciation of plant and equipment	2,748	1,300
Interest income	(199)	(485)
Operating profit / (loss) before working capital changes	(6,626)	(2,118)
(Increase) / decrease in receivables	7,306	(3,397)
(Increase) / decrease in inventories	(118)	(162)
(Decrease) / increase in payables	(458)	(3,630)
Cash (used in) / generated from operations	104	(9,307)
Taxes paid	(106)	(140)
<b>Net cash (used in) / generated from operating activities</b>	<b>(2)</b>	<b>(9,447)</b>
<b>Cash flows from investing activities</b>		
Interest received	199	485
Purchase of plant and equipment	(136)	(1,297)
Investment in jointly controlled entity	(6,793)	-
<b>Net cash (used in) / generated from investing activities</b>	<b>(6,730)</b>	<b>(812)</b>
Net (decrease) / increase in cash and cash equivalents	(6,732)	(10,259)
Cash and cash equivalents at beginning of the period	12,110	22,369
<b>Cash and cash equivalents at end of period</b>	<b>5,378</b>	<b>12,110</b>

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

**UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS****B Explanatory Notes Pursuant to MFRS 134****i Basis of Preparation & Changes in Accounting Policies****First-Time Adoption of Malaysian Financial Reporting Standards ("MFRS")**

These condensed consolidated interim financial statements, for the period ended 30 June 2013, have been prepared in accordance with MFRS 134 Interim Financial Reporting. These condensed consolidated interim financial statements also comply with IAS 34 Interim Financial Reporting issued by the International Accounting Standards Board. For the periods up to and including the the Group prepared its financial statements in accordance with applicable Financial Reporting Standards ("FRS").

These condensed consolidated interim financial statements are the Group's first MFRS condensed consolidated interim financial statements for part of the period covered by the Group's first MFRS annual financial statements for the year ending 30 June 2013. MFRS 1 First-Time Adoption of Malaysian Financial Reporting Standards has been applied.

There is no impact of the transition from FRS to MFRS to the financial position, financial performance and cashflow. This report should be read in conjunction with the audited financial statements for the year ended 30 June 2012 and the accompanying explanatory notes. The explanatory notes provide an explanation of events and transactions that are significant for an understanding of the changes in the financial position and performance of the Group since the year ended 30 June 2012.

**Significant Accounting Policies and Applications**

The audited financial statements of the Group for the year ended 30 June 2012 were prepared in accordance with FRS. Except for certain differences, the requirements under FRS and MFRS are similar. The significant accounting policies adopted in preparing this condensed consolidated interim financial statements are consistent with those of the audited financial statements for the year ended 30 June 2012.

The Company has changed its rate of depreciation for certain lab equipments from 20% to 33% per annum. This has resulted in an increase in the depreciation charge for the quarter amounting to RM1.3 million.

**ii Auditors' Report on Preceding Annual Financial Statements**

The audited financial statements for the year ended 30 June 2012 were not qualified.

**iii Seasonal and Cyclical Factors**

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

**iv Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow**

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period.

**v Material Changes in Estimates**

There were no material changes in the estimates that had effect(s) on the financial period.

**vi Debt and Equity Securities**

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

**vii Dividends Paid**

There were no dividends paid for the financial period.

**viii Segmental Information**

FRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Chief Operating Decision Maker in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the foreseeable future. Please refer to the financial statements presented in Part A of this announcement.

**MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD**

(Company No. 652790-V)

(Incorporated in Malaysia under the Companies Act, 1965)

**B Explanatory Notes Pursuant to MFRS 134 (cont.)**
**ix Valuation of Plant and Equipment**

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

**x Subsequent Events**

There were no material events subsequent to the end of the current financial period under review that have not been reflected.

**xi Changes in the Composition of the Group**

There were no changes in the composition of the Group, including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructuring and discontinuing operations for the financial period to date.

**xii Contingent Liabilities or Contingent Assets**

There was no contingent liability or contingent asset arising since the last audited annual balance sheet date as at 30 June 2012.

**xiii Capital Commitments**

There were no material capital commitments for the purchase of property, plant and equipment that were not provided for in the interim financial statements as at the end of the financial period.

**xiv Related Party Transactions**

Save as disclosed below, there were no significant related party transactions during the financial period to date:-

## a) Significant Related Party Transactions

for the financial period ended		4th Quarter		Year-to-Date	
		Current Year	Previous Year	Current Year	Previous Year
Related Party	Nature of Transaction	30.6.2013	30.6.2012	30.6.2013	30.6.2012
		(RM'000)	(RM'000)	(RM'000)	(RM'000)
Neuramatix, our ultimate holding company	Management fee payable to Neuramatix pursuant to Shared Services Agreement.	243	220	840	943
# Synamatix, our holding company	Exclusive licence fees payable to Synamatix with respect of software developed by Synamatix pursuant to Software License Agreement.	(63)	63	123	249
# Synamatix, our holding company	System maintenance fees payable to Synamatix for annual maintenance of licensed software pursuant to Software License Agreement.	(301)	301	602	1,204
		<b>(121)</b>	<b>584</b>	<b>1,565</b>	<b>2,396</b>

# Synamatix has waived the exclusive license fees and system maintenance fees for this period.

**B Explanatory Notes Pursuant to MFRS 134 (cont.)**
**xiv Related Party Transactions (cont.)**

## b) Compensation of Key Management Personnel (excluding directors)

	4th Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	30.6.2013	30.6.2012	30.6.2013	30.6.2012
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Salaries, allowances and bonuses	353	443	1,541	1,524
Contributions to defined contribution plan	32	16	102	66
Social security contributions	-	-	-	1
<b>Total short-term employee benefits</b>	<b>385</b>	<b>459</b>	<b>1,643</b>	<b>1,591</b>

**xv Cash and Cash Equivalents**

as at	Current Year	Previous Year
	30.6.2013	30.6.2012
	(RM'000)	(RM'000)
Cash on hand and at banks	78	180
Deposits with licensed banks	5,300	11,930
	<b>5,378</b>	<b>12,110</b>

**xvi Inventories**

There was no write-down of inventories during the financial period to date.

**C Explanatory Notes Pursuant to Appendix 9B, ACE Market Listing Requirements**

These condensed consolidated interim financial statements, for the period ended 30 June 2013, have been prepared in accordance with Paragraph 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa").

**i Performance of the Group**
Current Year 4th Quarter versus Previous Year 4th Quarter

For the fourth quarter ended 30 June 2013, the Group recorded a revenue of RM0.3 million, which represents a reduction of RM0.8 million as compared to a revenue of RM1.1 million for the fourth quarter in the preceding year.

For the current quarter, the Group recorded a loss before taxation of RM0.8 million as compared to a loss before taxation of RM1.6 million in the same quarter of the preceding year.

Contributions from the share of profits in the jointly controlled entity was the main reason for reduced losses.

Current Year-to-Date versus Previous Year-to-Date

The Group recorded a revenue of RM0.5 million, which represents a reduction of RM9.3 million as compared to a revenue of RM9.8 million in the previous year-to-date. We continue to see revenue from smaller projects and the decrease was mainly due to the successful completion of our projects with BiotechCorp and the Ministry of Science, Technology and Innovation ("MOSTI").

The Group registered a loss before taxation of RM8.8 million as compared to a loss before taxation of RM3.5 million in the corresponding period of the previous year. The loss before taxation was mainly due to lower revenue (RM0.5 million versus RM9.8 million).

**ii Comparison with Preceding Quarter's Results**

The comparison of this quarter's results with the preceding quarter is set out below.

for the financial period ended	Current Quarter 30.6.2013 (RM'000)	Preceding Quarter 31.3.2013 (RM'000)	Variance (RM'000)
Revenue	257	169	88
Profit / (loss) before tax	(756)	(2,350)	1,594

The Company recorded gains from its share of profits in the jointly controlled entity of RM1.1 million, reduced employee benefits and expense by RM0.8 million and waived system maintenance cost and exclusive license fees by RM0.7 million. These were offset by a charge of RM1.3 million due to the change in depreciation rate for the laboratory equipment.

**iii Prospects of the Group**

MGRC has developed genetic screening products for distribution via hospitals, specialist medical centres and other consumer market channels under the brand Dtect. There are now six products which screen for the genetic predisposition of non-communicable diseases. New products in the pipeline will also screen for an array of communicable and infectious diseases which will be rolled out on a progressive basis. While R&D efforts continue, management is focused on marketing activities and establishing distribution channels locally and in key international markets.

The recently acquired Clinipath Group represents an established network of around 800 primary care clinics and 8 hospitals/specialist medical centres for the Dtect products serving all major cities in Peninsular and East Malaysia. The value accretive aspects of this acquisition can be expected to materialise once their operations have been streamlined with those of the Company and post-acquisition synergies begin to be exploited.

Through the efforts of the Group's recently announced subsidiary, MGRC International Sdn. Bhd., interest in our products and services continues to grow internationally. As a result of this, several business and investment opportunities are being pursued.

**iv Variance from Profit Forecast**

The Group did not publish any profit forecast.

**MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD**

(Company No. 652790-V)

(Incorporated in Malaysia under the Companies Act, 1965)



**C Explanatory Notes Pursuant to Appendix 9B, ACE Market Listing Requirements (cont.)**
**v Taxation**

MGRC's BioNexus pioneer status accords the Company with tax exemption on its statutory income for qualifying activities. The Group's effective tax rate for the current financial year is thus lower than the Malaysian statutory tax rate of 25%.

Taxation for the financial period ended	4th Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	30.6.2013 (RM'000)	30.6.2012 (RM'000)	30.6.2013 (RM'000)	30.6.2012 (RM'000)
Malaysian income tax:				
Current period	12	27	50	121
Prior period	(2)	(5)	(2)	(5)
<b>Total</b>	<b>10</b>	<b>22</b>	<b>48</b>	<b>116</b>

The above tax has arisen in relation to interest income.

**vi Status of Corporate Proposal**

The acquisitions set out in the corporate proposal announced to Bursa on 20 July 2012 have been completed as per the announcement made to Bursa on 3 December 2012.

**vii Status of Utilisation of Proceeds from Issue of Shares**

The Company was listed on the ACE Market of Bursa on 5 October 2010 ("Date of Listing"). The Company raised RM18.5 million from its Initial Public Offering ("IPO") and the details of utilisation of such proceeds as at 30 June 2013 are as follows:

Utilisation of Proceeds Purpose Details (if available)	Initial Timeframe for Utilisation	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated		Explanation
				(RM'000)	(%)	
Capital expenditure	Within two (2) years from the Date of Listing	6,000	5,715	285	5%	#1
Laboratory equipment		900	900	-	0%	
Computer hardware & software						
R&D expenditure	Within two (2) years from the Date of Listing	1,510	941	569	38%	#1
Marketing expenditure	within three (3) years from the Date of Listing	2,000	1,403	597	30%	#1
Working capital	Within two (2) years from the Date of Listing	4,568	4,880	(312)	0%	#2
Listing expenses	Within one (1) month from the Date of Listing	3,490	3,178	312	0%	#2
Acquisition of jointly controlled entity		-	6,793	(1,451)		#1
<b>Total utilisation of funds</b>		<b>18,468</b>	<b>23,810</b>	<b>-</b>	<b>0%</b>	

#1 The under utilisation of these expenses was used to fund the acquisition of the Clinipath Group via the jointly controlled entity in accordance with a Resolution of the Directors dated 19 November 2012.

#2 The under utilisation of these expenses was adjusted to working capital.

**C Explanatory Notes Pursuant to Appendix 9B, ACE Market Listing Requirements (cont.)**
**viii Borrowings**

The Group does not have any borrowings as at 30 June 2013.

**ix Material Litigations**

As at the date of this announcement, there are no material litigations against the Group or taken by the Group.

**x Dividends**

No dividends were declared during the current financial year under review.

**xi EPS**

- a) **Basic EPS** Computed by dividing the profit / (loss), net of tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

Basic EPS for the financial period ended	4th Quarter		Year-to-Date	
	Current Year 30.6.2013	Previous Year 30.6.2012	Current Year 30.6.2013	Previous Year 30.6.2012
Profit / (loss), net of tax, attributable to owners of the parent (RM'000)	(766)	(1,603)	(8,801)	(3,660)
Weighted average number of ordinary shares of RM0.10 each in issue ('000)	94,100	94,100	94,100	94,100
<b>Basic EPS (sen)</b>	<b>(0.81)</b>	<b>(1.70)</b>	<b>(9.35)</b>	<b>(3.89)</b>

- b) **Diluted EPS** The Group does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.

**xii Disclosure of Realised and Unrealised Profits / (Losses)**

as at	30.6.2013 (RM'000)	30.6.2012 (RM'000)
Realised retained profits / (accumulated losses) of the Company	(4,970)	4,856
Realised profit / (loss) of a subsidiary	(13)	(5)
Realised profit / (loss) of a jointly controlled entity	1,033	-
<b>Group retained profits / (accumulated losses)</b>	<b>(3,950)</b>	<b>4,851</b>

**xiii Authorisation for Issue**

The interim financial statements were authorised for issue by the Board of Directors in accordance with a Resolution of the Directors dated 26 August 2013.